Evidence map›Paper›PMID 28217431›Full record

ArticleAllergo journal international2017

A novel experimental technology for testing efficacy of air purifiers on pollen reduction.

Karl-Christian Bergmann, Torsten Sehlinger, Julia Gildemeister, Torsten Zuberbier

Open access · hybridAbstract read
In one paragraph

Article in Allergo journal international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 15 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Karl-Christian BergmannAllergy-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Torsten SehlingerBluestone Technology GmbH, Woerrstadt, Germany.
Julia GildemeisterAllergy-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Torsten ZuberbierAllergy-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllergenic pollen exposure is mostly seen as an outdoor phenomenon but studies have shown an indoor exposure: different pollen species including birch and grass pollen in houses, schools, and shops are leading to long-lasting symptoms even after the pollen season because pollen settle on surfaces and re-enter the indoor air depending on ventilation. To reduce indoor pollen load, windows need to be closed and devices should be used: as pure wiping and cleaning of surfaces is mostly not sufficient, air cleaners may be helpful in reducing pollen counts in indoor environment.

objectiveThe efficacy of an air cleaner is usually described by the filtration rate of standard dust particle sizes which is not necessarily related to clinical efficacy.

methodsA novel study design was developed using the technical equipment of a new mobile exposure chamber to investigate participants with allergic rhinitis (individual observational, controlled, prospective, single arm study).

resultsThe tested air cleaner reduced the grass pollen-induced (4000 grass pollen/m

conclusionsThe novel study protocol is suitable for testing efficacy of air cleaners and the tested air cleaner is effective in reducing clinical symptoms due to grass pollen in an indoor environment.

Indexed as

Air purifierAllergic rhinitisEfficacyMobile exposure chamberPollen in-door exposure

Identifiers

PMID28217431
PMCPMC5288418
OpenAlexW2549736941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.